Abstract
Introduction and Objective: We evaluate the safety and efficacy of catheter-free LBO laser PVP for the treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). Methods: We prospectively evaluated our initial LBO laser PVP experience and the need for urethral catheterization. Results: Seventy consecutive patients were identified. 49 (70%) were discharged without (C-) and 21 (30%) were discharged with (C+) a urethral catheter. There were no significant differences in pre-operative parameters, including age (C-: 65 ± 10 vs. C+: 69 ± 9 years), AUASS (C-: 22 ± 6 vs. C+: 21 ± 6), Qmax (C-: 10 ± 4 vs. C+: 8 ± 3 ml/second), PVR (C-: 62 ± 105 vs. C+: 57 ± 82 ml) and prostate volume (C-: 65 ± 35 vs. C+: 86 ± 53 ml). There were no significant differences in laser time and energy usage. AUASS, Qmax and PVR values showed significant improvement within each group (P <0.05), but there were no significant differences between the two groups. All were outpatient procedures. 2/70 (2.9%) patients required catheter reinsertion in C+. The overall incidence of adverse events was low and did not differ between the two groups. Conclusions: Our experience suggests that catheter-free LBO laser PVP is safe and effective for the treatment of LUTS secondary to BPH.
| Original language | English |
|---|---|
| Pages (from-to) | 529-534 |
| Number of pages | 6 |
| Journal | Lasers in Surgery and Medicine |
| Volume | 40 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - Oct 2008 |
| Externally published | Yes |
Fingerprint
Keywords
- Benign prostatic hyperplasia
- Catheter duration
- KTP laser
- LBO laser
- Lower urinary tract symptoms
- Outcomes
ASJC Scopus subject areas
- Surgery
- Dermatology
Cite this
Catheter-free 120W lithium triborate (LBO) laser photoselective vaporization prostatectomy (PVP) for benign prostatic hyperplasia (BPH). / Spaliviero, Massimiliano; Araki, Motoo; Page, Jay B.; Wong, Carson.
In: Lasers in Surgery and Medicine, Vol. 40, No. 8, 10.2008, p. 529-534.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Catheter-free 120W lithium triborate (LBO) laser photoselective vaporization prostatectomy (PVP) for benign prostatic hyperplasia (BPH)
AU - Spaliviero, Massimiliano
AU - Araki, Motoo
AU - Page, Jay B.
AU - Wong, Carson
PY - 2008/10
Y1 - 2008/10
N2 - Introduction and Objective: We evaluate the safety and efficacy of catheter-free LBO laser PVP for the treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). Methods: We prospectively evaluated our initial LBO laser PVP experience and the need for urethral catheterization. Results: Seventy consecutive patients were identified. 49 (70%) were discharged without (C-) and 21 (30%) were discharged with (C+) a urethral catheter. There were no significant differences in pre-operative parameters, including age (C-: 65 ± 10 vs. C+: 69 ± 9 years), AUASS (C-: 22 ± 6 vs. C+: 21 ± 6), Qmax (C-: 10 ± 4 vs. C+: 8 ± 3 ml/second), PVR (C-: 62 ± 105 vs. C+: 57 ± 82 ml) and prostate volume (C-: 65 ± 35 vs. C+: 86 ± 53 ml). There were no significant differences in laser time and energy usage. AUASS, Qmax and PVR values showed significant improvement within each group (P <0.05), but there were no significant differences between the two groups. All were outpatient procedures. 2/70 (2.9%) patients required catheter reinsertion in C+. The overall incidence of adverse events was low and did not differ between the two groups. Conclusions: Our experience suggests that catheter-free LBO laser PVP is safe and effective for the treatment of LUTS secondary to BPH.
AB - Introduction and Objective: We evaluate the safety and efficacy of catheter-free LBO laser PVP for the treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). Methods: We prospectively evaluated our initial LBO laser PVP experience and the need for urethral catheterization. Results: Seventy consecutive patients were identified. 49 (70%) were discharged without (C-) and 21 (30%) were discharged with (C+) a urethral catheter. There were no significant differences in pre-operative parameters, including age (C-: 65 ± 10 vs. C+: 69 ± 9 years), AUASS (C-: 22 ± 6 vs. C+: 21 ± 6), Qmax (C-: 10 ± 4 vs. C+: 8 ± 3 ml/second), PVR (C-: 62 ± 105 vs. C+: 57 ± 82 ml) and prostate volume (C-: 65 ± 35 vs. C+: 86 ± 53 ml). There were no significant differences in laser time and energy usage. AUASS, Qmax and PVR values showed significant improvement within each group (P <0.05), but there were no significant differences between the two groups. All were outpatient procedures. 2/70 (2.9%) patients required catheter reinsertion in C+. The overall incidence of adverse events was low and did not differ between the two groups. Conclusions: Our experience suggests that catheter-free LBO laser PVP is safe and effective for the treatment of LUTS secondary to BPH.
KW - Benign prostatic hyperplasia
KW - Catheter duration
KW - KTP laser
KW - LBO laser
KW - Lower urinary tract symptoms
KW - Outcomes
UR - http://www.scopus.com/inward/record.url?scp=53249144149&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=53249144149&partnerID=8YFLogxK
U2 - 10.1002/lsm.20678
DO - 10.1002/lsm.20678
M3 - Article
VL - 40
SP - 529
EP - 534
JO - Lasers in Surgery and Medicine
JF - Lasers in Surgery and Medicine
SN - 0196-8092
IS - 8
ER -